eligibility_summary
Inclusion: Adults 18–70, consented, advanced/metastatic squamous NSCLC, measurable disease (RECIST 1.1), ECOG 0–1, adequate organs, tissue needed, contraception. Exclusion: active brain mets, other active cancer, effusions or uncontrolled pain, recent therapy/radiation/trial/surgery, unresolved tox >Grade 1, recent immunosuppression, ILD/pneumonitis or autoimmune disease, serious CV/CNS disease, active infection incl HBV/HCV/TB, bleeding risk, recent live vaccine, pregnancy, psych/substance issues, investigator discretion.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Trial NCT06512051 (Phase Ib/II) tests: 1) SHR-A2102 (investigational antitumor agent for injection, exact target/mechanism not disclosed in the registry, dose exploration ongoing). 2) Adebrelimab, a human anti–PD-L1 monoclonal antibody (immune checkpoint inhibitor) that blocks PD-1/PD-L1 to restore antitumor T-cell activity. 3) Cisplatin or Carboplatin, platinum-based cytotoxic chemotherapies that form DNA crosslinks causing replication stress and apoptosis. Targeted cells/pathways: Adebrelimab targets PD-L1 on tumor and immune cells to reinvigorate cytotoxic T cells via PD-1/PD-L1 pathway blockade, platinums target rapidly dividing tumor cells through DNA damage pathways. The specific cellular target/pathway for SHR-A2102 is not specified in the listing.